期刊
BRITISH JOURNAL OF CANCER
卷 94, 期 9, 页码 1233-1236出版社
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6603096
关键词
epirubicin; docetaxel; metastatic breast cancer; randomised trials; adjuvant anthracyclines
类别
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100mgm(-2) (D) with the combination of docetaxel 80mgm(-2) and epirubicin 75mgm(-2) (ED). The response rate (72 vs 79%), the progression-free survival ( median 9 vs 11 months) and the overall survival ( median 18 vs 21 months) were not significantly different between the ED (n=26) and D arms (n=25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据